Allergy Therapeutics plc (LON:AGY) had its Corporate rating reiterated by FinnCap

Analyst Ratings For Allergy Therapeutics plc (LON:AGY)

Story continues below

Today, FinnCap reiterated its Corporate rating on Allergy Therapeutics plc (LON:AGY).

There are 1 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Allergy Therapeutics plc (LON:AGY) is Buy with a consensus target price of GBX 46 per share, a potential .

Some recent analyst ratings include

  • 3/6/2019-Allergy Therapeutics plc (LON:AGY) had its Corporate rating reiterated by FinnCap
  • 9/26/2018-Allergy Therapeutics plc (LON:AGY) had its Buy rating reiterated by Numis Securities with a GBX 45 price target
  • 9/28/2017-Allergy Therapeutics plc (LON:AGY) had its Buy rating reiterated by Panmure Gordon
  • 4/4/2017-Allergy Therapeutics plc (LON:AGY) had its Buy rating reiterated by Stifel Nicolaus with a GBX 60 price target

    About Allergy Therapeutics plc (LON:AGY)
    Allergy Therapeutics plc engages in the research and development of allergy treatments. It sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees. The company's products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, and Venomil. It also develops clinical pipeline products that include vaccines for grass, tree, and house dust mite, as well as a peanut allergy vaccine that is in pre-clinical stage. The company primarily sells its products in European countries. Allergy Therapeutics plc was founded in 1934 and is based in Worthing, the United Kingdom.

    Recent Trading Activity for Allergy Therapeutics plc (LON:AGY)
    Shares of Allergy Therapeutics plc closed the previous trading session at 14,15 +0,40 2,91 % with shares trading hands.

    An ad to help with our costs